Saturday, October 31, 2009
This Times articles discusses AstraZeneca's settlement over off-label promotions. It got me wondering whether off-label prescribing is greater in psychiatry than in other specialties. Given the extreme flexibility of psychiatry's diagnostic system it would seem that practically all prescribing in psychiatry is "off-label." Yes, we may give people the diagnosis for which the studies on a particular drug were done, but how closely do the symptoms most of the people given these diagnoses match the symptom picture of the people in the study? Of course such prescribing is not truly off-label, but….
Tuesday, October 27, 2009
This New York Times article provides the latest on the continuing saga of the misuse of atypical antipsychotics. It will be interesting to track how long it will take until we are thoroughly chastened about the use of atypicals, especially in children. A comparative study of the histories of the rise and fall of various wonder treatments would be of interest-- insulin coma, focal infection etc.